Featured Research

from universities, journals, and other organizations

New agent may enhance effectiveness of radiotherapy

Date:
May 13, 2014
Source:
Manchester University
Summary:
The potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth has been demonstrated by scientists. There is increasing interest in using the body’s own immune system to attack tumor cells – a strategy that can be very effective without the side effects associated with conventional chemotherapy. Skin cancers, for instance, have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially harmful material.

Scientists from The University of Manchester -- part of the Manchester Cancer Research Centre -- have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth.

Related Articles


There is increasing interest in using the body's own immune system to attack tumor cells -- a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with radiotherapy and measured the effect on the primary tumor and the number of secondary tumors in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong immune system response from other immunotherapy agents in combination with radiation -- this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumor shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumors.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumors. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients," added Professor Stratford.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Amy L. Adlard, Simon J. Dovedi, Brian A. Telfer, Erina Koga-Yamakawa, Charlotte Pollard, Jamie Honeychurch, Timothy M. Illidge, Masashi Murata, David T. Robinson, Philip J. Jewsbury, Robert W. Wilkinson, Ian J. Stratford. A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. International Journal of Cancer, 2014; DOI: 10.1002/ijc.28711

Cite This Page:

Manchester University. "New agent may enhance effectiveness of radiotherapy." ScienceDaily. ScienceDaily, 13 May 2014. <www.sciencedaily.com/releases/2014/05/140513092330.htm>.
Manchester University. (2014, May 13). New agent may enhance effectiveness of radiotherapy. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2014/05/140513092330.htm
Manchester University. "New agent may enhance effectiveness of radiotherapy." ScienceDaily. www.sciencedaily.com/releases/2014/05/140513092330.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins